Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: Review of neuropsychiatric impairment in Alzheimer's disease

Current Medical Research and Opinion

Volumn 21, Issue 10, 2005, Pages 1631-1639

  Grossberg, George T ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Cholinesterase inhibition; Neuropsychiatric disturbance; Rivastigmine

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; CHOLINESTERASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; NIMODIPINE; PLACEBO; RIVASTIGMINE;

ABDOMINAL PAIN; AGGRESSIVENESS; AGITATION; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ANOREXIA; ANXIETY; APATHY; APPETITE; ASTHENIA; BEHAVIOR DISORDER; BIOACCUMULATION; BRAIN REGION; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; COMPARATIVE STUDY; CONFUSION; CONSTIPATION; DATA ANALYSIS; DELUSION; DEMENTIA; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; EMOTION; EUPHORIA; EXPERIMENTAL RAT; FATIGUE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEART DISEASE; HUMAN; IN VIVO STUDY; INSOMNIA; IRRITABILITY; LOCOMOTION; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MEDLINE; META ANALYSIS; MINI MENTAL STATE EXAMINATION; MOOD DISORDER; NAUSEA; NEUROBIOLOGY; NEUROFIBRILLARY TANGLE; NEUROMODULATION; NEUROPATHOLOGY; NEUROPSYCHIATRY; NONHUMAN; PARANOIA; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PHOBIA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PSYCHOSIS; RATING SCALE; RESPIRATORY TRACT DISEASE; REVIEW; SCORING SYSTEM; SENILE PLAQUE; SOMNOLENCE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TISSUE DISTRIBUTION; TREATMENT OUTCOME; VALIDATION PROCESS; VOMITING;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; HUMANS; MENTAL DISORDERS; META-ANALYSIS; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES;

EID: 27144524511     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X65402     Document Type: Review

References (56)

1. Grossberg GT. The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Int Psychogeriatr 2002;14 (Suppl 1):27-49
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22
3. Stevens T, Livingston G, Kitchen G, Manela M, Walker Z, Katona C. Islington study of dementia subtypes in the community. Br J Psychiatry 2002;180:270-66
4. Andersen K, Lolk A, Nielsen H, Kragh-Sorensen P. Prevalence and incidence of dementia in Denmark. The Odense study. Ugeskr Laeg 2000;162:4386-90
5. de Silva HA, Gunatilake SB, Smith AD. Prevalence of dementia in a semi-urban population in Sri Lanka: report from a regional survey. Int J Geriatr Psychiatry 2003;18:711-5
6. Levy ML, Cummings JL, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology 1999;45(Suppl 1):15-22
7. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-5
8. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc 1996;44:1078-81
9. O'Donnell BF, Drachman DA, Barnes HJ, Peterson KE, Swearer JM, Lew RA. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992;5:45-52
10. Brown LJ, Potter JF, Foster BG. Caregiver burden should be evaluated during geriatric assessment. J Am Geriatr Soc 1990;38:455-60
11. Pitkala KH, Laurila JV, Strandberg TE, Tilvis RS. Behavioral symptoms and the administration of psychotropic drugs to aged patients with dementia in nursing homes and in acute geriatric wards. Int Psychogeriatr 2004;16:61-74
12. Keefover RW. The clinical epidemiology of Alzheimer's disease. Neurol Clin 1996;14:337-51
13. Terry R, Masliah E, Hansen L. Structural basis of the cognitive alterations in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, editors. Alzheimer disease. New York: Raven Press, Ltd.; 1994. p. 179-96
14. Farber NB, Rubin EH, Newcomer JW, et al. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry 2000;57:1165-73
15. Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 2001;49:355-61
16. Geula C, Mesulam M-M. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, editors. Alzheimer disease. New York: Raven Press, Ltd.; 1994. p. 263-91
17. Court JA, Perry EK. Dementia: the neurochemical basis of putative transmitter orientated therapy. Pharmacol Ther 1991;52:423-43
18. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-6
19. Davies P. Studies on the neurochemistry of central cholinergic systems in Alzheimer's disease. In: Katzman R, Terry RD, Bick KL, editors. Alzheimer's disease: senile dementia and related disorders. New York: Raven Press; 1978. p. 453-9
20. Wright CI, Geula C, Mesulam M-M. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993;34:373-84
21. Geula C. Cholinergic pathophysiology in Alzheimer's disease. Consultant Pharmacist 2000;15:4-6
22. Mesulam M. Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer's disease. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz Ltd; 2000. p. 121-37
23. Guillozet AL, Smiley JF, Mash DC, Mesulam M-M. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997;42:909-18
24. Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996;153:1438-43
25. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14
26. Wood S, Cummings JL, Hsu M-A, et al. The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry 2000;8:75-83
27. Rösler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl 2002;127:20-36
28. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65
29. Reisberg B, Auer SR, Monteiro IM. Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Int Psychogeriatr 1996;8(Suppl3):301-8
30. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002; 47:64-70
31. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993;98:431-8
32. Jann M, Grossberg G. Cholinesterase inhibitors in the treatment of Alzheimer's disease. Consult Pharm 2000;15(Suppl B):7-15
33. Exelon (rivastigmine tartrate) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2001
34. Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 2000;20:1-12
35. Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000;15:242-7
36. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br Med J 1999;318:633-8
37. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002; 127:45-63
38. Trinh N-H, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. J Am Med Assoc 2003;289:210-6
39. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1(Suppl 1):S26-S34
40. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:243-9
41. Kurz A, Farlow M, Quarg P, Spiegel R. Disease stage in Alzheimer disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord 2004;18:123-8
42. Doraiswamy PM, Krishnan KR, Anand R, et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2002;26:705-12
43. Potkin SG, Anand R, Hartman R, Veach J, Grossberg G. Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:713-20
44. Grossberg G, Irwin P, Satlin A, Mesenbrink P, Spiegel R. Rivastigmine in Alzheimer disease: efficacy over two years. Am J Geriatr Psychiatry 2004;12:420-31
45. Cummings J, Anand R, Koumaras B, Hartman R. Rivastigmine provides behavioral benefits to Alzheimer's disease patients residing in a nursing home: findings from a 26-week trial. Neurology 2000;54(Suppl 3):A468-A469 [abstract S79.002]
46. Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Curr Med Res Opin 2004;20:1605-12
47. Suh DC, Arcona S, Thomas SK, et al. Risk of antipsychotic drug use among patients with Alzheimer's disease treated with rivastigmine. Drugs Aging 2004;21:395-403
48. Joachim CL, Morris JH, Selkoe DJ. Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases. Ann Neurol 1988;24:50-6
49. Perry RH, Irving D, Blessed G, Perry EK, Fairbairn AF. Clinically and neuropathologically distinct form of dementia in the elderly. Lancet 1989;1:166
50. Rocca WA, Hofman A, Brayne C, et al. The prevalence of vascular dementia in Europe: facts and fragments from 1980-1990 studies [EURODEM-Prevalence Research Group]. Ann Neurol 1991;30:817-24
51. Ballard CG, Ayre G, O'Brien J, et al. Simple standardised neuropsychological assessments aid in the differential diagnosis of dementia with Lewy bodies from Alzheimer's disease and vascular dementia. Dementia Geriatr Cogn Disord 1999;10: 104-8
52. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6
53. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999;13(Suppl3):S115-S123
54. Grace J, Daniel S, Stevens T, et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001;13:199-205
55. Moretti R, Torre P, Antonello RM, et al. Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. Int J Clin Pract 2004;58:346-53
56. Potkin SG, Anand R, Fleming K, et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol 2001;4:223-30